by Annabel Sedgwick
Share
by Annabel Sedgwick
Share
Venomtech®, a UK biotech leader since 2010, utilizes natural venoms from over 200 species for drug discovery studies. The team employs INTEGRA’s VOYAGER pipette for efficient venom-based screening assay production.
“Our core product is our Targeted-Venom Discovery Array™ (T-VDA), which include venoms from 12 species selected according to the target of interest. Our production process starts in 96 well stock plates, so we need to transfer to 384 well array plates, and so the ability to electronically adjust the tip spacing one-handed was a major part of the decision to choose the VOYAGER. It stood out in side-by-side comparisons in terms of the sheer ability of the instrument, as well as the service and interactions with INTEGRA. Its precision, light weight and quiet motor-drive were definitely key features in our decision. The repeat dispensing function is really important for our workflow, as it means you are not going backwards and forwards to your reservoir each time – making the process much faster – while the serial dilution function is perfect for creating standards with different concentrations. We bought our VOYAGER at least seven years ago, and it has been a serious workhorse for us – not just in production, but also for our R&D and QC work,” concluded Steve.
Visit the INTEGRA Biosciences website to learn more.
Microban® International – the global leader in antimicrobial additives and odor control solutions – has released a statement discrediting unwarranted claims about the safety and efficacy of antimicrobial technologies. This statement is intended to ensure that the public, consumers, and other stakeholders are equipped to make fully informed decisions, based on scientific reasoning. Making a clear distinction between public health and non-public health claims, Microban has explained the advantages of incorporating its antimicrobial additives into
Anion dysregulation is seen in numerous diseases, from cystic fibrosis and chronic pain, to autism and cancer. Researchers at the University of Dallas are investigating anion transport in vivo, developing novel tools to help analyze the effects of both normal and aberrant anion regulation at the molecular level, and are using INTEGRA’s PIPETBOY acu 2 to streamline their cell
June Medical is one of 48 organisations to be recognised for their excellence in innovation in this year’s Queen’s Awards for Enterprise. Now in its 55th year, the Queen’s Awards for Enterprise are the most prestigious business awards in the country – rewarding only the most outstanding achievements – with winning businesses able to use the esteemed
A report from the International Agency for Research on Cancer1 recently classified TiO2 as ‘possibly carcinogenic to humans’ by inhalation and similarly, the European Chemicals Agency2 recommended TiO2 be classified as a category 2 carcinogen (suspected of causing cancer). In contrast, antimicrobial technologies from Microban International are based on SilverShield®, the first patented antimicrobial solution